RxDoctor Payments Data

Rachel Regan, MD

Family Medicine · Springfield, OHNPI 1053940981

Payments from drug & device makers

$1,323in general payments, 2019–2025

Across 14 payments — averaging $94.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$321
  • GSK$265
  • AstraZeneca$212
  • E.r. Squibb & Sons, L.L.C.$125
  • Boehringer Ingelheim$124
  • Medtronic$106
  • plus $170 from 2 others

What the payments were for

  • Food & beverage$1,323100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,323 in reported general payments places this provider in the 65th percentile of 3,983 family medicine providers in Ohio.

See all family medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$56,206
Medicare patients
210
Services billed
624

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide61$67,135
JardianceEmpagliflozin67$66,497
EliquisApixaban64$59,748
OzempicSemaglutide39$58,693
XareltoRivaroxaban22$29,230
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$26,858
JanuviaSitagliptin Phosphate27$25,870
FarxigaDapagliflozin Propanediol22$25,030
Breo ElliptaFluticasone/Vilanterol23$13,591
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr17$9,156
Spiriva HandihalerTiotropium Bromide15$8,329
Albuterol Sulfate HfaAlbuterol Sulfate120$4,704
Atorvastatin Calcium324$3,354
Icosapent Ethyl11$2,649
Omeprazole148$2,316

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$66$67,13561 claims
Boehringer IngelheimJardiance$124$66,49767 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$265$49,60566 claims
AstraZenecaFarxiga$212$25,03022 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,983 family medicine providers in Ohio.

Other family medicine in Springfield

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →